---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-455669"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2026-11-10T21:55:25+00:00"
generated_at: "2026-11-10T21:57:06.168215+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Acrivon introduces ACR-525 and PKCθ inhibitor preclinical I&I programs targeting EoE

## Summary
- Nov 10, 2026 R&D webcast introduced ACR-525 and a PKCθ inhibitor, both preclinical, with initial development plans in eosinophilic esophagitis (EoE).
- Dr. Arjan Bredenoord (Amsterdam UMC), EoE principal investigator, covered epidemiology and unmet need; Dr. Evan Dellon (UNC) reviewed EoE standard of care.
- Programs were identified with Acrivon's AI-driven AP3 platform and mark the company's entry into immunology and inflammation.
- No preclinical data, IND timing, trial endpoints or financial terms were disclosed; the posted exhibit is only a title slide.

## SEC filing metadata
- accession: 0001193125-26-455669
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2026-11-10T21:55:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312526455669/0001193125-26-455669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526455669/acrv-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-455669
- JSON: https://secwatch.observer/filing/0001193125-26-455669.json
- Plain text: https://secwatch.observer/filing/0001193125-26-455669.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.